Gilead (GILD) Stock Edges Lower Amid HSV Licensing Update
Gilead Sciences saw muted trading activity Monday as investors weighed its expanded antiviral pipeline. Shares dipped 0.10% to $124.16, with after-hours trading showing marginal recovery to $124.35. The stock traded within a narrow $2 range on below-average volume of 6.52 million shares.
The biopharma firm bolstered its infectious disease portfolio through new HSV program licensing—a strategic MOVE signaling focus on next-generation therapies beyond its core HIV business. Market reaction remained tempered ahead of Gilead's scheduled presentation at January's healthcare investor conference, where pipeline updates could shift sentiment.
Analysts maintain constructive ratings, citing stable HIV revenue and promising clinical assets. With $154 billion market capitalization, Gilead's incremental moves in antivirals may compound into long-term growth drivers.
